Literature DB >> 1833116

A relative cost-effectiveness analysis of different methods of screening for diabetic retinopathy.

M J Sculpher1, M J Buxton, B A Ferguson, J E Humphreys, J F Altman, D J Spiegelhalter, A J Kirby, J S Jacob, H Bacon, S B Dudbridge.   

Abstract

The relative cost and cost-effectiveness of different methods of screening diabetic patients for sight-threatening retinopathy are assessed. The resource costs per screening visit, both to the health service and to patients, of ophthalmoscopic examination by primary screeners including general practitioners, hospital physicians, and ophthalmic opticians are estimated together with those of a similar screening test by ophthalmological clinical assistants. The total resource cost per screen of screening using non-mydriatic photography is also estimated. Using estimates of sensitivity, specificity, and prevalence generated in the screening of 3318 diabetic patients in three UK centres, the relative cost-effectiveness of screening methods is estimated in terms of their cost per true positive case detected. On the assumption that a patient makes a special trip for eye screening, the cost per true positive case detected for primary screeners ranges from 633 pounds for a GP-screened group in one centre to 1079 pounds for another GP-screened group in a second centre; the cost per true positive case detected of photography ranges from 497 pounds for a camera that is taken to general practices in one centre to 1546 pounds for a hospital-based camera. Relative cost-effectiveness changes if, in some contexts, the screening can take place without requiring an additional patient visit, and is strongly related to the relative sensitivity of the screening methods and to the prior probability (prevalence or incidence) of retinopathy in the diabetic population.

Entities:  

Mesh:

Year:  1991        PMID: 1833116     DOI: 10.1111/j.1464-5491.1991.tb01671.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  10 in total

1.  Costs of diabetes. A methodological analysis of the literature.

Authors:  E Pagano; M Brunetti; F Tediosi; L Garattini
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

2.  Role of diabetes.

Authors:  K G Alberti
Journal:  BMJ       Date:  1991-09-28

3.  Cost effectiveness analysis of screening for sight threatening diabetic eye disease.

Authors:  M James; D A Turner; D M Broadbent; J Vora; S P Harding
Journal:  BMJ       Date:  2000-06-17

Review 4.  Pharmacoeconomics of diabetes surveillance and detection programmes.

Authors:  P D Home
Journal:  Pharmacoeconomics       Date:  1995       Impact factor: 4.981

5.  Screening for diabetic retinopathy. GPs in south London have direct access to screening service.

Authors:  S Smith
Journal:  BMJ       Date:  1995-11-04

6.  Telemedical diagnosis of retinopathy of prematurity: accuracy of expert versus non-expert graders.

Authors:  Steven L Williams; Lu Wang; Steven A Kane; Thomas C Lee; David J Weissgold; Audina M Berrocal; Daniel Rabinowitz; Justin Starren; John T Flynn; Michael F Chiang
Journal:  Br J Ophthalmol       Date:  2009-12-02       Impact factor: 4.638

7.  Prompting the clinical care of non-insulin dependent (type II) diabetic patients in an inner city area: one model of community care.

Authors:  B Hurwitz; C Goodman; J Yudkin
Journal:  BMJ       Date:  1993-03-06

8.  Use of mobile screening unit for diabetic retinopathy in rural and urban areas.

Authors:  G P Leese; S Ahmed; R W Newton; R T Jung; A Ellingford; P Baines; S Roxburgh; J Coleiro
Journal:  BMJ       Date:  1993-01-16

9.  Assessment of colour vision as a screening test for sight threatening diabetic retinopathy before loss of vision.

Authors:  G L Ong; L G Ripley; R S B Newsom; A G Casswell
Journal:  Br J Ophthalmol       Date:  2003-06       Impact factor: 4.638

10.  Grader agreement, and sensitivity and specificity of digital photography in a community optometry-based diabetic eye screening program.

Authors:  Luckni Sellahewa; Craig Simpson; Prema Maharajan; John Duffy; Iskandar Idris
Journal:  Clin Ophthalmol       Date:  2014-07-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.